Abbott Medical

Abbott Park, Illinois, USA All United States companies → — Founded 1888

Healthcare Conglomerate Medical Device / Hardware Point-of-Care Diagnostics

Cardiology Internal Medicine

Cardiology AI Clinical Decision Support & Reference Surgical AI

Public — N/A

Claim this company

Products

OPTIS Mobile Next Imaging

Abbott Medical

Cardiology AI

The OPTIS™ Mobile Next Imaging System by Abbott Medical is an AI-powered, transportable intravascular imaging system for cath labs, offering high-resolution OCT and coronary physiology measurements to guide PCI procedures with enhanced efficiency and informed decision-making.

Assert-IQ

Abbott Medical

Cardiology AI

The Assert-IQ™ Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders.

Enterprise

See all 2 products →

About Abbott Medical

Abbott Laboratories, often referred to in its medical capacity as Abbott Medical, is a global healthcare leader with a comprehensive portfolio spanning medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals. For physicians, Abbott provides a wide array of innovative solutions designed to improve patient outcomes and streamline healthcare delivery. This includes advanced cardiovascular and neuromodulation devices, state-of-the-art diagnostic tools for core lab, molecular, point-of-care, and rapid diagnostics, as well as science-based nutrition products.

While not exclusively a ‘healthcare AI company’ in the startup sense, Abbott has significantly accelerated its integration of artificial intelligence across its businesses. The company leverages AI for applications such as micrometer-level medical imaging (e.g., Ultreon software for guiding stent placement), predicting heart attacks through machine learning algorithms, and enhancing diabetes care with algorithmic AI in products like FreeStyle Libre. Abbott is also exploring generative AI for personalized nutrition and meal planning with features like Libre Assist, and utilizing predictive algorithms for diagnostic instrument maintenance. Their approach to AI is guided by principles of responsibility, safety, transparency, fairness, and human oversight.

Focus Areas

Medical devices (cardiovascular neuromodulation diabetes care with AI-powered glucose monitoring and imaging) diagnostics (core lab molecular point-of-care rapid diagnostics with AI for predictive maintenance and disease diagnosis) nutritional products branded generic medicines and increasingly AI-driven solutions for metabolic coaching personalized nutrition and clinical decision support.

Business Intelligence

Key Investors	N/A
Partnerships	LibreView integration with Epic EHRs, a:care program for healthcare professionals in emerging markets
Acquisitions	Exact Sciences Corporation (planned acquisition), St. Jude Medical (2017), Alere Inc. (2017)
Technology	Cloud-based AI algorithms, generative AI models, secure AI environment across platforms, digital health solutions (AlinIQ), edge computing (implied by devices)
FDA Clearances	867 (total 510(k) cleared devices since 1976); AI-enabled products include Ultreon Software, FreeStyle Libre systems (including Libre Assist feature), Assert-IQ insertable cardiac monitor system, Libre Rio, and Lingo. cleared products (estimated)

What Physicians Need to Know

Medical Devices (Cardiovascular, Neuromodulation, Diabetes Care)

Abbott specializes in a broad range of medical devices, including advanced cardiovascular solutions for heart failure, irregular heartbeat, and mitral regurgitation, often leveraging minimally invasive procedures and remote monitoring. Their neuromodulation therapies address chronic pain and movement disorders with spinal cord stimulation (SCS) and deep brain stimulation (DBS) systems. In diabetes care, they offer AI-powered continuous glucose monitoring (CGM) systems like FreeStyle Libre, which includes features like Libre Assist for real-time, personalized meal guidance.

Diagnostics (Core Lab, Molecular, Point-of-Care, Rapid)

Abbott provides innovative diagnostic solutions across core laboratory, molecular, point-of-care, and rapid diagnostics. These solutions are designed for speed, accuracy, and efficiency in screening, diagnosing, and monitoring a vast range of health conditions. A key differentiator is the integration of AI for predictive maintenance of instruments (e.g., AlinIQ Always On Services) to reduce downtime and for advanced disease diagnosis, such as algorithms to more accurately determine if a patient is having a heart attack.

Nutritional Products

The company offers a comprehensive portfolio of nutritional products, including pediatric nutrition (e.g., Similac), adult nutrition (e.g., Ensure), and specialized dietary needs (e.g., Glucerna). Increasingly, Abbott is integrating AI-driven solutions for metabolic coaching and personalized nutrition to provide tailored support.

Branded Generic Medicines

Abbott's branded generic medicines portfolio is primarily focused on emerging markets, providing trusted and accessible therapies across various therapeutic areas such as gastroenterology, women's health, cardiometabolic disorders, pain management, central nervous system, respiratory, oncology, and immunology.

AI-Driven Solutions & Technology Stack

Abbott is a leader in AI integration, leveraging algorithmic and generative AI across its businesses for solutions like AI-powered glucose monitoring (Libre Assist for meal impact prediction), imaging AI to guide optimal stent placement (Ultreon software), AI for more accurate classification of atrial fibrillation (Assert-IQ), predictive maintenance in diagnostics, and clinical decision support. Their technology stack includes advanced AI/ML algorithms, sensor technology, imaging platforms, connected devices, data analytics, cloud computing, and a secure AI environment at enterprise scale.

Physician Tip

For physicians, Abbott Medical's offerings provide significant advantages. Leverage their AI-powered devices, such as the FreeStyle Libre system with Libre Assist, for real-time glucose insights and personalized meal guidance, which can enhance patient adherence and outcomes in diabetes management. Utilize their advanced imaging AI (e.g., Ultreon software) in cardiovascular procedures for more precise diagnostics and optimal intervention placement. Benefit from AI-driven predictive maintenance in diagnostic instruments to ensure operational efficiency and reduce unexpected downtime in your lab. Embrace their AI-driven clinical decision support tools to streamline workflows, gain deeper insights from patient data, and potentially reduce administrative burden, allowing more focus on patient care. Abbott's commitment to responsible AI, with human oversight, ensures these advanced technologies are applied ethically and safely, supporting better, more efficient, and patient-centric services.

Abbott's AI solutions are designed for seamless integration within their existing product ecosystems, such as the Libre app for continuous glucose monitoring and AlinIQ for laboratory instruments. The company emphasizes building a secure AI environment across platforms, utilizing cloud infrastructure and robust data systems for scalable processing and actionable insights. This focus on integrated, intelligent systems aims to streamline workflows for healthcare providers and empower patients with accessible tools and information for enhanced self-management and shared decision-making.

At a glance

Founded 1888

HQ Abbott Park, Illinois, USA · United States

Team size Approximately 115,000

CEO Robert B. Ford

Funding Public — N/A

FDA clearances 867 (total 510(k) cleared devices since 1976); AI-enabled products include Ultreon Software, FreeStyle Libre systems (including Libre Assist feature), Assert-IQ insertable cardiac monitor system, Libre Rio, and Lingo. (estimated)

Products 2

Products by Abbott Medical

2 products in the directory

OPTIS Mobile Next Imaging

Abbott Medical

Cardiology AI

Assert-IQ

Abbott Medical

Cardiology AI

Enterprise

What the Web Says

Abbott Medical receives mixed reviews, with strong positive feedback regarding compensation and benefits, but significant negative sentiment concerning work-life balance, company culture, and product reliability. While some employees praise the opportunities for career growth and the caliber of colleagues, many express dissatisfaction with management, micromanagement, and a demanding work environment. Product reviews, particularly for their glucose monitoring systems, frequently highlight issues with accuracy, defects, and poor customer service.

Overall: Mixed

Strengths

Good pay and benefits.
Opportunities for learning and career growth.
Talented and knowledgeable colleagues.
Supportive management in some areas.
Improved patient care through healthcare software.
Strong brand and ethical standards.

Limitations

Poor work-life balance and demanding environment.
Toxic company culture, micromanagement, and politics.
Frequent layoffs and high employee turnover.
Substandard product quality and technical issues, especially with glucose monitors.
Poor customer service and lack of product support.
Lack of work-from-home options despite previous availability.

Based on reviews from: G2, Reddit, Indeed.com, Comparably, Trustpilot

Last updated: 2026-07-18

Videos

News, demos, and interviews about Abbott Medical.

Loading videos...

Videos load interactively. If none appear, search YouTube for Abbott Medical →

View all on YouTube

Press & Coverage

MedTech Dive

Abbott wins FDA approval for updated heart failure monitoring device | MedTech Dive

Abbott received FDA approval for CardioMEMS Hero, a smaller and lighter remote heart failure monitoring device, making it easier for patients to use and travel with. The device works with existing CardioMEMS sensors and is expected to benefit from recent reimbursement changes.

2026-03

Omnicuris

Abbott Medical Devices Drive Solid 2026 Profit Growth | Omnicuris

Abbott's medical device segment saw a 9% growth in Q2 2026, driven by electrophysiology, rhythm management, and continuous glucose monitoring technologies like FreeStyle Libre. The acquisition of Exact Sciences in early 2026 significantly boosted diagnostic sales by 42%.

2026-07

BioWorld

Abbott raises FY2026 guidance, bullish on CGM, electrophysiology | BioWorld

Abbott Laboratories raised its full-year 2026 adjusted EPS guidance due to strong Q2 performance in its medical devices and cancer diagnostic units. The company anticipates accelerated growth in its diabetes unit, driven by continuous glucose monitors, and is investing in its electrophysiology portfolio.

2026-07

Fierce Biotech

Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecast - Fierce Biotech

Abbott reported stronger-than-expected Q2 results with a 42% gain in diagnostics and a 9% increase in medical devices, leading to an increased full-year EPS guidance. The growth was significantly boosted by the $23 billion acquisition of Exact Sciences in November 2025.

2026-07

TradingView

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook - TradingView

Abbott's medical device segment grew 8.5% year-over-year in Q1 2026, driven by strong performance in cardiovascular devices, particularly electrophysiology and rhythm management. The company is also seeing momentum in its continuous glucose monitoring sales and has completed patient enrollment for its CATALYST trial.

2026-05

accessdata.fda.gov

MAUDE Adverse Event Report: ABBOTT MEDICAL MASTERS SERIES HEART COATED AORTIC VALVED GRAFT

An FDA MAUDE adverse event report details a malfunction with an Abbott Medical Masters Series Heart Coated Aortic Valved Graft, where a research article reviewed surgical approaches for ascending aorta surgery. The article mentioned the use of St. Jude Medical conduit valves, now part of Abbott.

2026-05

ClinicalTrials.gov

Abbott DBS Post-Market Study of Outcomes for Indications Over Time | ClinicalTrials.gov

Abbott Medical Devices is sponsoring an international, prospective, multicenter, observational, post-market study (ADROIT) to evaluate the long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for various indications. The study, which began in November 2019, is estimated to be completed by September 2030.

2026-01

Citeline Insights

Abbott: Wall Street Braces for Medical Device Momentum Against Nutrition Headwinds

Abbott Laboratories reported Q1 2026 earnings with strong medical device momentum, particularly with the Volt Pulsed Field Ablation system, despite headwinds in its Nutrition business and a Class I recall of certain FreeStyle Libre 3 sensors. The pending acquisition of Exact Sciences is expected to transform its diagnostics portfolio.

2026-04

Frequently Asked Questions

How does Abbott Medical's integrated portfolio of medical devices, diagnostics, and AI-driven solutions benefit patient care and clinical workflows?

Abbott's diverse portfolio spans medical devices, diagnostics, nutritionals, and branded generic medicines, aiming to provide comprehensive healthcare solutions. This integration, increasingly powered by AI, helps streamline clinical workflows, offer more precise diagnostics, and enable personalized patient management across various therapeutic areas.

What are Abbott's key offerings in AI-powered glucose monitoring and diagnostics, and how do these enhance patient management and predictive capabilities?

Abbott's FreeStyle Libre systems utilize AI algorithms for continuous glucose monitoring, providing real-time insights for diabetes management. In diagnostics, AI is used in solutions like Ultreon software for cardiovascular imaging to guide stent placement and in predictive algorithms for instrument maintenance and disease diagnosis. These technologies enhance patient management by offering actionable data and improving diagnostic accuracy and efficiency.

Can you elaborate on Abbott's commitment to regulatory compliance and data security across its medical devices and AI-driven platforms?

Abbott is committed to designing its AI systems to be safe, secure, and to protect data and privacy appropriately, guided by a five-point Responsible AI framework. The company emphasizes upholding scientific standards, ensuring human oversight, and being transparent about AI usage and data handling. They also have a Cybersecurity Coordinated Disclosure Program for reporting vulnerabilities and regularly issue product advisories to maintain security.

What kind of support and training does Abbott provide to healthcare professionals for implementing and optimizing their advanced medical technologies and AI solutions?

Abbott offers extensive education and training programs for healthcare professionals, including the a:care program for adherence support and the Abbott Education Network for cardiovascular and neuromodulation training. For diabetes care, the FreeStyle Portal provides e-learning modules, case studies, and training resources to help clinicians confidently support patients and use the latest technology. These resources aim to address clinical, technical, and procedural challenges, facilitating optimal use and improved patient outcomes.

How does Abbott Medical approach pricing and value for its comprehensive range of products, including medical devices, diagnostics, and nutritional products, for healthcare systems?

Abbott aims to deliver value through innovation, scale, and diversification across its medical devices, diagnostics, nutritionals, and established pharmaceuticals. While the company has faced challenges with pricing in its nutrition business due to rising costs impacting demand, it is taking strategic actions to improve volume growth. Abbott focuses on providing life-changing technologies that improve care, reduce costs, and strengthen its competitive position.

What is Abbott's strategy for partnerships and interoperability to ensure seamless integration of its devices and AI solutions within existing hospital IT infrastructures?

Abbott actively pursues partnerships to integrate its technologies within healthcare IT infrastructures. For example, data from its FreeStyle Libre systems can be integrated directly into Epic's electronic health record systems, streamlining access to glucose monitoring information for clinicians. Additionally, Abbott has integrated its precision oncology testing portfolio into Flatiron Health's OncoEMR platform, allowing clinicians to order tests and access results within their existing workflow. These collaborations aim to improve workflow efficiency and enhance patient care through seamless data access.

Given the rapid evolution of healthcare technology, what is Abbott Medical's long-term vision for innovation, particularly concerning AI and personalized medicine?

Abbott's long-term vision is centered on driving consistent organic growth through innovation, expanding global healthcare access, and leveraging next-generation technologies like AI and biowearables. The company sees AI as a pillar for growth, aiming to use it to streamline workflows for healthcare providers, reduce burnout, and empower patients with tools for better health conversations and self-management. This includes developing AI-driven solutions for metabolic coaching, personalized nutrition, and clinical decision support.

Related Companies

Suggest an Edit →